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Abstract
Objective: The concepts of mild cognitive impairment (MCI) and subjective cognitive decline (SCD) have been proposed to 
identify individuals in the early stages of Alzheimer’s disease (AD), or other neurodegenerative diseases. One approach to val-
idate these concepts is to investigate the relationship between pathological brain markers and cognition in those individuals.
Method: We included 126 participants from the Consortium for the Early Identification of Alzheimer’s disease-Quebec 
(CIMA-Q) cohort (67 SCD, 29 MCI, and 30 cognitively healthy controls [CH]). All participants underwent a complete 
cognitive assessment and structural magnetic resonance imaging. Group comparisons were done using cognitive data, and 
then correlated with hippocampal volumes and white matter hyperintensities (WMHs).
Results: Significant differences were found between participants with MCI and CH on episodic and executive tasks, but 
no differences were found when comparing SCD and CH. Scores on episodic memory tests correlated with hippocampal 
volumes in both MCI and SCD, whereas performance on executive tests correlated with WMH in all of our groups.
Discussion: As expected, the SCD group was shown to be cognitively healthy on tasks where MCI participants showed 
impairment. However, SCD’s hippocampal volume related to episodic memory performances, and WMH to executive func-
tions. Thus, SCD represents a valid research concept and should be used, alongside MCI, to better understand the preclin-
ical/prodromal phase of AD.
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In spite of major research effort, the exact pathophysio-
logical events leading to Alzheimer’s disease (AD) remain 
largely unexplained. Yet, one major research advance over 
the last years was to show that the pathological cascade 
leading to AD most likely begins decades before the earliest 
clinical symptoms occur (Bateman et  al., 2012; Iturria-
Medina et  al., 2016; Leuzy, Heurling, Ashton, Schöll, & 
Zimmer, 2018; Price & Morris, 1999). It is generally be-
lieved that a better understanding of the earlier phases of 
AD will contribute to identifying causal mechanisms and 
eventually develop effective disease-modifying therapies.
Many authors have described a cognitive continuum 
from being without symptoms, to expressing a subjective 
complaint, to being objectively impaired, all in parallel 
with an accumulation of neuropathological markers and 
symptoms in a continuum from asymptomatic AD to de-
mentia (Albert et al., 2011; Jack et al., 2010; Sperling et al., 
2011). The term mild cognitive impairment (MCI) has been 
proposed to represent the stage on this continuum when 
cognitive impairments are present, but not sufficiently se-
vere for the person to meet criteria for AD or other neu-
rodegenerative diseases (Albert et al., 2011; Petersen et al., 
1999). More recently, it has been proposed that a subjec-
tive cognitive decline (SCD) stage extends the spectrum of 
AD to an earlier phase than that of MCI (Cheng, Chen, & 
Chiu, 2017; Jessen, Wolfsgruber, et al., 2014). SCD might 
also represent a very early phase of other neurodegener-
ative diseases. Persons with SCD complain about their 
memory but present scores within the normal range on 
standardized neuropsychological tests. It has been shown 
that a significant proportion of those individuals will later 
develop MCI and AD dementia, particularly if they display 
biomarker evidence of AD (Eckerström et al., 2017) or ex-
press worry about this perceived change in cognitive ability 
in addition to their memory complaints (Jessen, Amariglio, 
et al., 2014; Reisberg, Shulman, Torossian, Leng, & Zhu, 
2010). Hence, SCD might be considered as an interesting 
construct to study the first clinico-pathological manifest-
ations of AD (Dubois et al., 2016; Sperling et al., 2011). 
However, it is a new classification and remains to be better 
understood and validated. In particular, it might prove 
useful to compare persons with SCD with those meeting 
criteria for MCI as the latter is now fairly well character-
ized. Furthermore, SCD, and to a lesser extent MCI, both 
constitute heterogeneous groups (Mendonça, Alves, & 
Bugalho, 2016). Determining that there are coherent re-
lationships between neural markers of age-related neuro-
degenerative diseases and cognition would support these 
concepts as early manifestations of AD neurodegeneration, 
and possibly contribute to defining a pattern of brain–cog-
nition relationships within these groups.
Hippocampal atrophy, the degree of which can be meas-
ured with anatomical magnetic resonance imaging (MRI), 
is often used as a biomarker of neurodegeneration in prod-
romal AD. Indeed, the medial temporal lobe, which includes 
the hippocampus and surrounding cortices, is known to 
be one of the earliest sites of pathological changes in AD 
(Price et al., 2001). MRI studies have highlighted a reduc-
tion of hippocampal volume in MCI (Du et al., 2001; van 
de Pol et al., 2007). Several studies also demonstrated that 
SCD is associated with longitudinal hippocampal atrophy 
(Cherbuin, Sargent-Cox, Easteal, Sachdev, & Anstey, 2015; 
Perrotin et  al., 2015). As the hippocampus plays an im-
portant role in episodic memory (Squire & Zola-Morgan, 
1991), it is expected that in the preclinical AD phase, 
inter-individual variability in memory performance would 
be related to anatomical modifications associated with 
hippocampal volume loss, even if the measured memory 
changes remain within the range of normality. For instance, 
Cantero, Iglesias, Van Leemput, and Atienza (2016) and 
Flier and coworkers (2004) both reported an association 
between lower volumes in specific hippocampal regions 
and cognitive vulnerability in SCD. However, both studies 
were done with relatively small samples, 48 in the former 
and 20 self-referred memory complainers from hospital 
outpatient services in the latter.
In addition, white matter hyperintensities (WMHs) rep-
resent a common feature in the typical elderly population 
(Birdsill et al., 2014), but also in patients with a stroke and 
in pathological aging (Wardlaw, Smith, & Dichgans, 2013). 
WMH would reflect microstructural damages to the white 
matter that are typically localized around the ventricles or 
in the deep white matter (DeCarli, Fletcher, Ramey, Harvey, 
& Jagust, 2005). It is generally believed that WMHs signal 
non-AD-related small-vessel diseases as they are associated 
with vascular risk factors and vascular diseases. However, 
a large number of recent studies suggest that WMH may 
play a role in early AD (for review, see Radanovic et al., 
2013) because they frequently co-occur with the AD pa-
thology. WMH might also contribute to dementia appear-
ance and symptomatology, considering that there is an 
accelerating cognitive decline in persons with MCI who 
present with this marker (Wolf, Ecke, Bettin, Dietrich, & 
Gertz, 2000). For these reasons, WMHs are often studied 
in early AD (Birdsill et al., 2014; Liu, Braidy, Poljak, Chan, 
& Sachdev, 2018), over and above their possible associ-
ation with non-AD pathologies (Wardlaw et  al., 2013). 
Despite a growing number of studies on WMHs in AD 
and MCI (Hirono, Kitagaki, Kazui, Hashimoto, & Mori, 
2000; Jorm et al., 2004; van Rooden et al., 2018), their ef-
fect on the cognition of persons with SCD remains unclear. 
Most studies have reported that a larger volume of WMH 
is related to executive functioning deficits (de Groot et al., 
2001; Villeneuve & Belleville, 2012), while some point to a 
link between WMHs and memory abilities (Li et al., 2016; 
van Rooden et al., 2018). Thus, it is important to include 
WMH in studies identifying the relation between cognition 
and MRI brain markers in SCD and MCI.
The goal of the present study is to investigate the re-
lationship between episodic memory, executive func-
tions, and MRI markers of neurodegeneration defined 
by hippocampal volume and vascular integrity in SCD 
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and MCI. More precisely, we predicted that in these two 
groups, memory performance would be specifically related 
to hippocampal volume and that executive function perfor-
mance would be specifically related to WMH.
Method
Participants
This study relied on the data collected by the Consortium 
pour l’identification précoce de la maladie d’Alzheimer 
– Québec (CIMA-Q – Quebec Consortium for the Early 
Identification of Alzheimer’s disease). Participants in the 
CIMA-Q cohort lived in the community and were recruited 
from different sources such as memory clinics, advertise-
ments in electronic media, and ads posted in the community. 
Participants for this study were recruited from the cities of 
Montréal, Sherbrooke, and Québec City. The study has re-
ceived approval from the coordinating ethic committee of 
the IUGM. Participants gave their written informed con-
sent before enrollment in the study, and for the different 
components of the project.
Inclusion/Exclusion Criteria
CIMA-Q participants were at least 65 years old and native 
French or English speakers to represent the Canadian bi-
lingual context. The CIMA-Q study recruited individuals 
along the spectrum of AD, from cognitively healthy con-
trols (CH), to SCD, MCI, and clinically probable AD.
Participants met criteria for MCI based on the National 
Institute on Aging and the Alzheimer’s Association 
(NIA-AA) clinical criteria for MCI (Albert et al., 2011): 
(a) a reported decline of their memory; (b) an objective 
memory impairment according to education-adjusted 
normative values on the Logical Memory II subtest of 
the Wechsler Memory Scale (WMS III; Weschler, 1997), 
that is, a score between 2 and 6 for 0–7  years of edu-
cation, 4 and 9 for 8–15  years of education, or 8 and 
11 for ≥16  years of education; (c) a score between 20 
and 26 on the Montreal Cognitive Assessment (MoCA; 
Nasreddine et  al., 2005); and (d) a score of 0.5 on the 
Clinical Dementia Rating Scale.
The criteria for cognitively healthy participants were: 
(a) no memory complaint or worry; (b) a normal score 
on education-adjusted normative values on the WMS-
III Logical Memory II subtest, that is, a score of >3 for 
0–7  years of education, >5 for 8–15  years of education, 
or >9 for ≥16 years of education; (c) a performance above 
26/30 on the MoCA; and (d) a score of 0 on the Clinical 
Dementia Rating Scale (Morris, 1993).
Participants with SCD had to have scores within the 
same normality range on the Logical Memory II subtest, 
MoCA, and Clinical Dementia Rating Scale (see above for 
CH), but had to have reported that their memory was not 
as good as it used to be and that it worried them.
Other inclusion and all exclusion criteria (e.g., for AD 
participants) are listed in Supplementary Material S1. The 
CIMA-Q cohort is constructed to reflect the type of patients 
encountered in a typical clinical setting. We thus restricted 
the number of exclusion criteria based on co-morbidities to 
a minimum (see list of exclusions) as long as participants 
met the accepted parameters indicated by the diagnostic 
criteria.
Design
CIMA-Q developed a large-scale, multicenter, longitudinal 
protocol, which includes standardized neuroimaging, cog-
nitive assessment (for additional information, see website, 
http://www.cima-q.ca/, and design paper, Belleville et  al., 
under review), and biological sampling with training and 
quality control procedures. All material was prepared 
in French and English and when possible, cognitive tests 
were selected or developed to have equivalent versions in 
both languages. The first wave of enrollment and testing 
was done between 2015 and 2017 and included 290 par-
ticipants in total. A telephone pre-screening interview was 
first conducted and the Telephone – Mini-Mental State 
Examination (t-MMSE; Newkirk et al., 2004) was admin-
istered to review exclusion/inclusion criteria. Then, par-
ticipants were invited to a clinical diagnosis assessment 
completed by a nurse and a physician (via standardized 
checklists using accepted criteria). They then came for a 
session where they received neuropsychological testing. 
MRI-compatible participants were also invited to partici-
pate in a third session for MRI examination. For this study, 
we present data from the 126 non-demented participants 
(67 SCD, 29 MCI, and 30 CH) who completed the cogni-
tive test battery, as well as the anatomical MRI, of the first 
CIMA-Q wave.
Cognitive Assessment of Episodic Memory and 
Executive Function
The study was designed to reduce issues of circularity, as 
we used tasks that were different for inclusion criteria from 
those used to assess our hypotheses. Two tasks from the 
CIMA-Q battery were used to assess the relationship be-
tween episodic memory and hippocampal volume. To re-
duce the number of comparisons, we used delayed word 
recall and Face-Name association, two tasks that were re-
ported to be among the most sensitive predictors of pro-
gression from MCI to dementia based on a meta-analysis 
of prospective predictive studies (Belleville, Fouquet, 
Duchesne, Collins, & Hudon, 2014). The Memoria Word 
Recall test (Chatelois et  al., 1993) is a 15-word memory 
task measured with free and cued recall. The Face-Name 
test (Brambati, for CIMA-Q) is an associative memory test 
where participants learn the association between a face and 
a first name (see Figure 1) and are then asked for immediate 
and delayed recall of the name associated with each face. 
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We analyzed the free recall portion of the word recall and 
the delayed portion of the Face-Name association task. In 
both cases, larger scores represent better performance.
Three tasks examined the relationship between exec-
utive functions and WMHs. First, we used the Semantic 
Fluency test, which reflects semantic integrity while im-
posing demands upon executive control processes, as it re-
quires lexical search, effortful retrieval, attention-shifting, 
and sequencing (Belleville et al., 2017; Zhao, Guo, & Hong, 
2013). In this task, participants are asked to give as many 
animal names as possible within 60 s. A larger score rep-
resents better performance. The ratio between completion 
time of Trail B and Trail A was used as a measure of reac-
tive flexibility (Strauss, Sherman, Spreen, & Spreen, 2006). 
Here, a larger score represents poorer performance. Finally, 
a computerized version of the Hayling test (Bélanger & 
Belleville, 2009; Belleville, Rouleau, & Van der Linden, 
2006; from the original Hayling test Burgess & Shallice, 
1997) was used to assess inhibition (inhibition score). In 
this test, participants are presented with sentences that are 
missing the last word and are asked to complete it with an 
unrelated word. A larger inhibition score represents better 
performance.
Anatomical MRI
Brain imaging followed the standardized Canadian 
Dementia Imaging Protocol (https://www.cdip-pcid.ca/), 
which includes T1-weighted, PD-T2-weighted, T2*, FLAIR, 
30-direction diffusion, and T2*-weighted gradient-echo 
EPI at rest acquisitions. As this is a multicentric cohort, 
different MRI apparatuses were used from GE Medical 
Systems (Discovery), Philips Healthcare (Achieva; Ingenia), 
and Siemens Healthcare (Tim Trio; Prisma). Each scanner 
used a 20-channel head coil. The parameters for the dif-
ferent sequences were harmonized across MRI models to re-
duce variability and increase comparability (for details, see 
design paper, Duchesne et al., (2019), and Supplementary 
Table S1). For the purposes of this study, we specifically 
analyzed the T1-weighted and FLAIR acquisitions.
Image Processing and Analysis
Image preprocessing included magnetic field-related signal 
inhomogeneity correction and linear affine registration 
of FLAIR to the T1-weighted sequence. Hippocampal 
segmentation was performed using the FreeSurfer 5.3.0 
software (http://surfer.nmr.mgh.harvard.edu/), a proce-
dure fully described in Fischl and coworkers (2004). Once 
segmented, visual quality control was used to determine 
segmentation accuracy. The remaining raw left and right 
hippocampal volumes in standardized space were trans-
formed into z-scores according to normative data adjusting 
for age, sex, estimated total intracranial volume, scanner 
type, and scanner strength (Potvin, Mouiha, Dieumegarde, 
& Duchesne, 2016). As for WMH analysis, neuroimaging 
data processing was performed on FLAIR sequences using 
the volBrain pipeline (Manjón & Coupé, 2016), a method 
available through the volBrain online web interface (http://
volbrain.upv.es). To correct for head size difference between 
each subject, total WMH volume was expressed as a per-
centage of the intracranial cavity volume. A more general 
measure of the vascular burden was also proposed through 
the Hachinski scale (Hachinski, Lassen, & Marshall, 1974), 
providing an ischemia score and differentiating neurode-
generative dementia from vascular dementia using only 
clinical data.
Behavioral and MRI Comparisons and 
Multimodal Analyses
Group comparisons of clinical, behavioral, and brain 
measures, as well as multimodal analyses, were done with 
the Statistical Package for the Social Sciences (IBM-SPSS 
Statistics, version 25). Group comparisons were done for 
demographic values and hippocampal measures using 
analyses of variance (ANOVAs) for continuous variables 
or chi-squared analyses for discrete ones. Behavioral per-
formances for each task and WMH were analyzed with 
separate analyses of covariance (ANCOVAs) using Group 
(MCI, SCD, and CH) as a between-subject factor and con-
trolling for age. When there was a Group main effect, 
Bonferroni’s post hoc analyses were conducted to locate 
the source of the group difference. In order to assess the 
relationship between cognition and MRI brain markers, we 
computed Pearson correlations (one-tailed due to a priori 
hypotheses on the directionality of the effect) between per-
formance on cognitive tests and brain markers separately 
for each group. We focused our interest on the correl-
ations between memory and hippocampal volumes, and 
between executive functions and WMH. We also analyzed 
the correlation between memory and WMH, and between 
executive functions and hippocampal volumes, to be sure 
Figure 1. Face-Name task (Brambati, for CIMA-Q).
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that the first set of relationships were specific and not re-
flecting some general pattern of poor brain integrity being 
associated with poorer cognition. To compare the relative 
contribution of MRI markers, these were entered in a mul-
tiple linear regression model with backward elimination of 
nonsignificant variables as predictors of cognition.
Results
Demographic Data, Cognitive Performance, 
and MRI Measures
Demographic data, cognitive performances, and MRI 
measures are presented in Table 1. The groups were compa-
rable with regards to sex and years of education. However, 
participants with MCI were slightly older than CH and 
SCD, therefore age was controlled for in our analyses of 
behavioral performance. Individuals with SCD were un-
impaired on measures of episodic memory and executive 
function relative to CH, whereas MCI differed from CH 
on both memory tasks (Memoria free recall, p < .05; Face-
Name delayed recall, p < .05), and on two measures of 
executive functions (Trail B/A, p < .05; Semantic Fluency, 
p < .05). MCI also showed lower performance than SCD 
on memory and executive tasks, p <.05, with the excep-
tion of the Face-Name and Hayling tasks. The group-wise 
analysis of MRI measures highlighted lower left and right 
hippocampal volume in MCI than in SCD and CH (left: p 
≤ .001 and right: p < .05), but no significant difference be-
tween SCD and CH. As for WMH, there was no significant 
difference between groups, but MCI and CH differed on 
the Hachinski score (p < .05).
Multimodal Analyses
After false discovery rate control, Pearson tests (see Table 2 
for details) revealed significant correlations between memory 
performance and hippocampal volumes (see Figure  2). 
More precisely, in MCI, smaller left hippocampal volume 
was associated with lower performance on the Memoria 
free recall (r = .427; p = .010) and lower delayed face-name 
association, just short of significance (r = .308; p = .052). 
In SCD, a smaller right hippocampal volume was associ-
ated with lower Memoria free recall (r =  .267; p =  .015) 
and lower delayed performance in Face-Name association 
(r = .319; p = .005), and smaller left hippocampal volume 
was associated with lower performance on the Memoria 
free recall just short of significance (r = .202; p = .052). In 
CH, lower performance on the Memoria free recall was as-
sociated with bigger left hippocampal volume (r = −.314; 
p = .049). Importantly, hippocampal volumes were not as-
sociated with performance on executive measures.
There were significant negative correlations between 
WMH and executive functions (see Figure 3). In the MCI 
group, larger volumes of WMH were associated with lower 
Hayling scores (r  =  −.520; p  =  .007), and with a higher 
Table 1. Demographic, WMH, and Hippocampal Data, and Performance on Selected Neuropsychological Measures of 
Participants With Subjective Cognitive Decline, Mild Cognitive Impairment, and Cognitively Healthy Controls
CH SCD MCI
P values
SCD vs. CH MCI vs. CH SCD vs. MCI
N 30 67 29    
Sex (Male/Female) 9/21 25/42 14/15 ns ns ns
Age 71.9 ± 5.7 72.3 ± 5.1 76.3 ± 5.3 1.000 0.005* 0.003*
Education (Years) 16.1 ± 3.8 15.2 ± 3.2 15.0 ± 3.0a ns ns ns
WMH (%) 0.2 ± 0.1 0.3 ± 0.3 0.4 ± 0.3 0.334 0.101 1.000
Left hippocampal volume (z-score) -0.2 ± 0.9 -0.2 ± 1.1 -1.3 ± 1.3 1.000 < 0.001** < 0.001**
Right hippocampal volume (z-score) -0.03 ± 1.0 -0.2 ± 1.2 -1.1 ± 1.3 1.000 0.002* 0.002*
Hachinski 0.6 ± 1.0 1.1 ± 1.2a 1.5 ± 1.6 0.260 0.022* 0.420
MoCA 28.5 ± 1.4 27.9 ± 1.3 24.8 ± 2.1 0.364 < 0.001** < 0.001**
MMSE 25.2 ± 1.0 24.4 ± 1.9 24.3 ± 1.6 ns ns ns
Logical Memory 14.7 ± 4.6 13.4 ± 4.4 9.6 ± 4.3 0.528 < 0.001** 0.001*
Memoria free word recall (/15) 13.8 ± 1.4 13.0 ± 1.9 11.3 ± 3.9 0.523 0.004* 0.033*
Face-Name delayed recall (/9) 5.4 ± 1.7 4.4 ± 2.4b 2.8 ± 2.3 0.151 0.002* 0.099
Hayling inhibition test (/30) 18.6 ± 4.1c 19.9 ± 4.9d 19.0 ± 4.9d ns ns ns
Semantic Fluency test 21.1 ± 5.0 19.5 ± 4.7 16.4 ± 4.0 0.373 0.003* 0.039*
Trail test Time B/ Time A 1.9 ± 0.6 2.0 ± 0.7 2.8 ± 1.9 1.000 0.013* 0.007*
Note: CH  =  cognitively healthy; ns  =  nonsignificant analysis before post hoc comparisons; MCI  =  mild cognitive impairment; MMSE  =  Mini-Mental State 
Examination; MoCA = Montréal Cognitive Assessment; SCD = subjective cognitive decline; WMH = white matter hyperintensities. Unless otherwise indicated, 
values are mean ± SD. p Values refer to significant analysis of variance (demographic and imaging data) and analysis of covariance models (neuropsychological 
tests controlled for age), followed by post hoc pairwise comparisons with Bonferroni correction.
aData missing for one subject. bData missing for two subjects. cData missing for three subjects. dData missing for five subjects.
*p < .05. **p < .001.
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ratio between completion time of Trail B/Trail A (r = .436; 
p = .013). In SCD individuals, larger volumes of WMH were 
associated with lower Fluency scores (r = −.257; p = .018) 
and with lower scores on the Hayling test (r  =  −.301; 
p = .009). In CH, larger volumes of WMH were only asso-
ciated with a higher ratio between completion time of Trail 
B/Trail A  (r  =  .518; p  =  .002). No significant correlation 
was found between WMH and any of the memory meas-
ures for all groups.
In order to be sure that our correlations were robust 
and not driven by some potential outliers, we used fully 
adjusted regression models of the relationship between 
MRI brain measures and cognition. Results are provided in 
Supplementary Table S2. The majority of the associations 
mentioned above using Pearson correlation analyses were 
confirmed by the adjusted models. In particular, they con-
firmed the relation between the right hippocampus and 
Face-Name memory in SCD, the relation between the left 
hippocampus and the delayed word recall in MCI, and the 
relation between WMH and executive functions in SCD 
(Fluency and Hayling) and in CH (Trail).
Discussion
The aim of this study was to assess whether memory and 
executive functions were related to the MRI anatomical 
features that are typically associated with AD in per-
sons with SCD and MCI. Our results indicate a specific 
Figure 2. Scatter plots and lines of best fit for the relation between 
(a) left hippocampal volume and Memoria free recall score; (b) right 
hippocampal volume and memoria free recall score; (c) left hippocampal 
volume and Face-Name recall score; and (d) right hippocampal volume 
and Face-Name recall score. CH = cognitively healthy; MCI = mild cog-
nitive impairment; SCD = subjective cognitive decline.
Figure 3. Scatter plots and lines of best fit for the relation between 
(a) white matter hyperintensities and the Hayling inhibition score; (b) 
White matter hyperintensities and the Fluency score; and (c) White 
matter hyperintensities and Memoria free recall score. CH = cognitively 
healthy; MCI = mild cognitive impairment; SCD = subjective cognitive 
decline; WMH = white matter hyperintensities. 
Table 2. Pearson Correlations (one-tailed significance) Between Performance on Cognitive Tests and Brain Markers Separately 
for Each Group
    
Memoria Face-Name Hayling Fluency Trail
L-Hcp R-Hcp L-Hcp R-Hcp  WMH  
CH Pearson −0.281 −0.314* −0.144 −0.032 0.183 0.175 0.518*
p values 0.070 0.049 0.228 0.870 0.186 0,183 0,002
SCD Pearson 0.202t 0.267* 0.228* 0.319* −0.301* −0.257* 0.181
p values 0.052 0.016 0.034 0.005 0,009 0.018 0.071
MCI Pearson 0.427* 0.125 0.292 0.308t −0.520* −0.269 0.436*
p values 0.010 0.258 0.062 0.052 0.007 0.092 0.013
Note: Pearson correlation r scores and p values. CH = cognitively healthy; L-Hcp = left hippocampus; MCI = mild cognitive impairment; R-Hcp = right hippo-
campus; SCD = subjective cognitive decline; WMH = white matter hyperintensities.
*p < .05. tp = .052.
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relation between lower memory performance and smaller 
hippocampal volume in MCI and SCD, and a specific re-
lation between larger volumes of WMH and lower execu-
tive functions in SCD, MCI, and CH. We acknowledge the 
importance of reducing circularity issues in this study. In 
doing so, the tests employed to measure cognition were in-
dependent from those used for diagnosis and inclusion cri-
teria. Nonetheless, the CIMA-Q cohort is meant to focus 
on AD and, by design, criteria for MCI require the pres-
ence of a memory problem. Thus, our study might miss 
MCI participants with non-memory problems, a pattern 
that could characterize the prodromal phase of non-AD 
neurodegenerative diseases. Even though persons with 
SCD are not expected to be impaired on typical neuropsy-
chological measures, we predicted a correlation between 
brain markers and cognition in this group, similar to what 
we would observe in MCI individuals. The same corre-
lation pattern suggests that similar brain changes occur 
during SCD and MCI stages and that these brain changes 
account for inter-individual cognitive differences in both 
groups. Our results thus support the presence of a con-
tinuum between SCD and MCI. In contrast, we did not 
expect such a correlational pattern in CH. WMH was also 
expected to be associated with executive functions in both 
SCD and MCI.
Thus, an important goal was to assess the relation be-
tween MRI markers and cognition in SCD. The rationale 
is that if the complaint of persons with SCD reflects a 
cognitive change which is felt by the individual, but re-
mains undetected by traditional tests, one would expect 
inter-individual variability on brain measures to relate to 
inter-individual variability in cognitive performance. This 
was assessed by examining correlations between MRI 
markers and cognitive performance. As expected, we found 
positive correlations between hippocampal volume and 
memory performance in both MCI and SCD. Smaller right 
hippocampal volume was associated with worse Face-
Name recall in SCD, and in MCI to a lesser extent. This 
is consistent with studies showing that Face-Name recall 
is a sensitive measure in the early stages of AD (Rubiño & 
Andrés, 2018) and that lower performance on Face-Name 
recall in MCI (Rentz et al., 2011) and SCD (Sanabria et al., 
2018) is associated with beta amyloid burden in brain re-
gions implicated in memory processes. We also found that, 
smaller left hippocampal volume was associated with 
worse delayed word recall in MCI and in SCD to a lesser 
extent. However, in CH, we observe an inverse association, 
in which smaller left hippocampal volume was associated 
with better performance during this task. Although this 
seems counterintuitive, it is not entirely unexpected based 
on prior findings (for review and meta-analysis, see Van 
Petten, 2004). Although the loss of hippocampal volume is 
often associated with memory decline in AD, studies exam-
ining the relationship between hippocampal volume and 
memory have found both positive and negative relation-
ships (for review and meta-analysis, see Van Petten, 2004).
When examining group differences of hippocampal 
volume, we found a preferential reduction of bilateral 
hippocampi in MCI compared to CH, and no significant 
difference was highlighted between SCD and CH. This 
finding leads us to think that, despite the fact that cerebral 
changes in SCD already seem to influence their memory per-
formance, their anatomy is more similar to that of healthy 
controls, than to that of MCI individuals when exam-
ining group effects. Noteworthily, inspection of Figure  2 
indicates that a fair proportion of SCD individuals have 
hippocampal volumes in the low range value overlapping 
with that of MCI, particularly for the right hippocampus. 
Given that these individuals also display lower memory 
scores, it is consistent with the notion that these early brain 
modifications produce subtle cognitive changes, which 
bring on a complaint before becoming clinically measur-
able (Cherbuin et al., 2015).
We found an association between WMH and execu-
tive functions in all three groups: WMH correlated with 
the Fluency and Trail tests in SCD, with the Hayling and 
Trail tests in MCI, and with the Trail in CH. Thus, the rela-
tion between WMH and executive functions does not seem 
to be specific to MCI and SCD and may be relevant to a 
broader range of individuals. This is consistent with nu-
merous studies showing that increased vascular burden is 
associated with lower executive functions in older adults 
(Au et  al., 2006; Smith et  al., 2011; Van Petten et  al., 
2004). It is important to acknowledge that Fluency tests 
are multidimensional, whereby reflecting multiple cogni-
tive processes at once. Thus, our findings could represent 
a link between WMH and other cognitive processes, not 
restricted to executive functioning. Some studies have in-
dicated that white matter abnormalities have an effect 
on executive performance, but can also impair episodic 
memory by affecting connections between the cortex and 
subcortical structures (Smith et al., 2011). This would be 
particular to older adults at risk of developing AD (SCD or 
individuals with abnormal amyloid-β, for example, Freeze 
et al., 2016). However, we did not find evidence of a rela-
tionship between WMH volumes and memory in this study.
As expected, the SCD group did not differ from CH on 
cognitive measures. This is unsurprising as it corresponds 
with this group’s definition (Perrotin et al., 2017; Sperling 
et al., 2011). Even if subtle cognitive modifications take place 
within the SCD phase, they do not seem sufficiently severe to 
be revealed by a standard cognitive evaluation. In addition, 
the SCD participants report a cognitive decline compared 
to their own past performances, but this intra-individual 
change is not typically assessed by a standard battery of 
tests. It is of note that there is some cognitive heterogeneity 
within the SCD group (Mendonça et al., 2016), and this is 
highlighted in Figures 2 and 3, where some SCD individuals 
show mild cognitive deficits. Furthermore, the performance 
of persons with SCD on the Face-Name association task 
stands between that of MCI and CH and did not signifi-
cantly differ from either of them, suggesting that they have a 
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very mild deficit in this task. Associative memory is known 
to be impaired early in MCI. Therefore, in the present case, 
we used an association between a face and a first name be-
cause it is particularly challenging and not easily amenable 
to any form of semantic encoding. This might make the task 
particularly sensitive to the early memory problems that per-
sons with SCD experience. It is important to acknowledge 
that we used the Logical Memory subtest of the Wechsler 
Memory Scale to diagnose unimpaired cognition in SCD. 
This test might be less sensitive to the very mild symptoms 
of SCD than the more demanding face-name memory test. 
Yet, given that the SCD group is closer to CH than to MCI 
overall, it is fair to say that the subjective complaint of these 
individuals remains as one of the few directly observable 
symptoms (Jessen, Wolfsgruber, et al., 2014).
In contrast, persons with MCI differ from both CH and 
SCD on two measures of memory and on two measures of 
executive functions. The finding of an executive impairment 
is worth noting because MCI subjects from the CIMA-Q 
cohort are so-called amnestic MCI, in that they were de-
fined on the basis of a memory impairment. Our results 
confirm prior studies indicating that amnestic MCI is often 
a multiple-domain MCI, due to additional impairment on 
measures of executive functions (Bélanger & Belleville, 
2009; Belleville, Gilbert, et al., 2006; Johns et al., 2012).
This study has some limitations that call for future work. 
First, the three groups presented in this study are unequal 
and therefore do not have the same statistical power. This 
may partly explain the smaller number of significant correl-
ations in the MCI group. It would therefore be interesting 
to test the same hypotheses in a larger cohort. Recruitment 
source is another important aspect to consider because the 
majority of our participants were recruited from the com-
munity. Many studies have shown that MCI participants 
recruited from the community are less impaired and less 
likely to progress to dementia than those recruited from 
memory clinics, as demonstrated in a study by Farias, 
Mungas, Reed, Harvey, and DeCarli (2009), among others. 
Studies examining the effect of recruitment source in SCD 
individuals are scarce but one recent study indicated an im-
pact on the degree of progression from SCD to an MCI 
diagnosis (Snitz et al., 2018). It remains to be seen whether 
the recruitment methods in the present study influenced our 
study outcomes. Finally, as this was a cross-sectional study, 
we are unable to examine causal relationships between neu-
roimaging markers and cognitive decline. A follow-up may 
identify those who progress to AD dementia among SCD 
and MCI subjects, and thus truly stand in the prodromal 
phase of AD. A  2-year follow-up assessment is currently 
underway with the CIMA-Q cohort, hence contributing to 
longitudinal information on progression of the disease.
Conclusion
This study consolidates the notion that SCD represents a 
valid research target to better understand the preclinical 
phase of AD and other neurodegenerative diseases. The no-
tion of SCD complements the criteria that were established 
to characterize MCI by bringing an even earlier dimension 
to AD and similar age-related neurodegeneration. This may 
have important implications, as studying this population 
might contribute to identifying the processes that con-
tribute to AD at a very early stage. This is critical because 
disease-modifying treatments should ideally be offered as 
early as possible (Cheng et al., 2017). Thus, the SCD and 
MCI periods may be fundamental for drug development 
and implementation of very early secondary prevention 
approaches.
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